[go: up one dir, main page]

MX2022010588A - Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. - Google Patents

Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.

Info

Publication number
MX2022010588A
MX2022010588A MX2022010588A MX2022010588A MX2022010588A MX 2022010588 A MX2022010588 A MX 2022010588A MX 2022010588 A MX2022010588 A MX 2022010588A MX 2022010588 A MX2022010588 A MX 2022010588A MX 2022010588 A MX2022010588 A MX 2022010588A
Authority
MX
Mexico
Prior art keywords
virus
cov
recombinant poxvirus
vaccine against
based vaccine
Prior art date
Application number
MX2022010588A
Other languages
English (en)
Inventor
Seth Lederman
David Evans
Ryan Noyce
Scott J Goebel
Original Assignee
Tonix Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Ltd filed Critical Tonix Pharma Ltd
Publication of MX2022010588A publication Critical patent/MX2022010588A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere en varios aspectos a un poxvirus recombinante que comprende un ácido nucleico que codifica una proteína del virus SARS-CoV-2, a métodos para producir dichos virus y al uso de los mismos. Los poxvirus recombinantes son muy adecuados, entre otras cosas, como vacunas virales protectoras contra el virus SARS-CoV-2.
MX2022010588A 2020-02-26 2021-02-26 Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. MX2022010588A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062981997P 2020-02-26 2020-02-26
US202063114514P 2020-11-16 2020-11-16
PCT/US2021/020119 WO2021174142A1 (en) 2020-02-26 2021-02-26 Recombinant poxvirus based vaccine against sars-cov-2 virus

Publications (1)

Publication Number Publication Date
MX2022010588A true MX2022010588A (es) 2023-02-09

Family

ID=75267580

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010588A MX2022010588A (es) 2020-02-26 2021-02-26 Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.

Country Status (11)

Country Link
US (1) US20210260182A1 (es)
EP (1) EP4110386A1 (es)
JP (1) JP2023515582A (es)
KR (1) KR20220165731A (es)
CN (1) CN116348135A (es)
AU (1) AU2021226592A1 (es)
BR (1) BR112022016992A2 (es)
CA (1) CA3173996A1 (es)
IL (1) IL295925A (es)
MX (1) MX2022010588A (es)
WO (1) WO2021174142A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115529817A (zh) * 2020-02-14 2022-12-27 吉奥瓦科斯公司 疫苗及其诱导针对sars-cov2的免疫应答的用途
US20240269266A1 (en) * 2020-04-14 2024-08-15 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine
MX2022014387A (es) * 2020-05-17 2023-04-11 Hope City Vacunas contra coronavirus a base de vaccinia ankara sintetica modificada (smva).
US20230295655A1 (en) * 2020-07-31 2023-09-21 Tokyo Metropolitan Institute Of Medical Science Recombinant vaccinia virus
TW202334434A (zh) * 2021-07-21 2023-09-01 中央研究院 對抗嚴重急性呼吸道症候群冠狀病毒2型之基於痘病毒的疫苗及使用該疫苗的方法
CN113621076A (zh) * 2021-08-31 2021-11-09 南华大学 一种针对新冠病毒变异毒株Delta的融合蛋白、喷鼻式疫苗及其制备方法和应用
WO2023133227A2 (en) * 2022-01-06 2023-07-13 Board Of Regents, The University Of Texas System A sars-cov-2 human parainfluenza virus type 3-vectored vaccine
WO2023168286A1 (en) * 2022-03-01 2023-09-07 Tonix Pharmaceuticals Holding Corp. Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
EP4316514A1 (en) * 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vectors and their use as vaccine against sars-cov-2
GB2624391A (en) * 2022-11-15 2024-05-22 Univ Cape Town Recombinant LSDV vectored bovine coronavirus antigen constructs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004777A (en) * 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
EP1668112A4 (en) * 2003-06-20 2009-04-29 Protein Sciences Corp SARS IMMUNOGENOUS EXPRESSING VECTORS, SUCH VECTORS OR EXPRESSION PRODUCTS COMPRISING THOSE COMPOSITIONS, PROCESSES AND TESTS FOR THE PREPARATION AND USE THEREOF
US20070275010A1 (en) * 2003-09-18 2007-11-29 Mark Feinberg Mva Vaccines
WO2005103259A1 (en) * 2004-04-26 2005-11-03 University Health Network Sars-cov nucleocapsid protein epitopes and uses thereof
WO2006022215A1 (ja) * 2004-08-23 2006-03-02 The Japan Health Sciences Foundation SARS-コロナウイルスタンパク質をコードするDNAを保有する組換えワクチニアウイルスDIs株、およびその利用
CN101020055B (zh) * 2006-02-16 2012-08-08 中国疾病预防控制中心性病艾滋病预防控制中心 基于复制型痘苗病毒载体的sars疫苗
EP3045181B1 (en) * 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
WO2017047089A1 (en) * 2015-09-16 2017-03-23 Shin Nippon Biomedical Laboratories, Ltd. Vaccine compositions
NZ752893A (en) * 2016-11-02 2025-10-31 Tonix Pharma Ltd Synthetic chimeric poxviruses
CN112543806B (zh) 2018-05-02 2025-06-06 戴维·埃文斯 合成嵌合痘苗病毒
US10906944B2 (en) * 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines

Also Published As

Publication number Publication date
TW202146428A (zh) 2021-12-16
JP2023515582A (ja) 2023-04-13
CA3173996A1 (en) 2021-09-02
KR20220165731A (ko) 2022-12-15
WO2021174142A1 (en) 2021-09-02
US20210260182A1 (en) 2021-08-26
IL295925A (en) 2022-10-01
CN116348135A (zh) 2023-06-27
EP4110386A1 (en) 2023-01-04
BR112022016992A2 (pt) 2022-10-25
AU2021226592A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
MX2022009962A (es) Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2.
EP4104854A3 (en) Multivalent vaccines for rabies virus and coronaviruses
MX2017002791A (es) Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante.
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
EA201590304A1 (ru) Вакцина рекомбинантного модифицированного вируса осповакцины анкара респираторно-синцитиального вируса
MX2019003682A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
ZA201707985B (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
ZA202305129B (en) Recombinant hvt and uses thereof
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
AU2014232363A8 (en) Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
ZA201900641B (en) Viral vaccines
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
PH12017500419B1 (en) Recoded arbovirus and vaccines
BR112019008584A2 (pt) vacinas de mosaico para vírus de doença de pé-e-boca de sorotipo a
PT1370668E (pt) Vacinas de vector baseadas em leporipox
WO2013097022A3 (pt) Proteínas recombinantes, polinucleotídeos e vacinas contra herpesvírus bovinos
MX358118B (es) Vacuna contra el virus de la leucemia bovina.
WO2024259078A3 (en) Anti-tick vaccines and methods of use thereof
CA3009928A1 (en) Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
EA202193150A2 (ru) Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)